5767-36-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96% is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96% is employed as a key intermediate in the synthesis of agrochemicals, aiding in the creation of effective compounds for agricultural use.
Used as a Reagent in Organic Synthesis:
4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96% is used as a reagent in the preparation of various heterocyclic compounds, facilitating the synthesis of complex organic molecules for diverse applications.
Used in the Synthesis of Anti-Cancer Agents:
As a key intermediate, 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96% plays a crucial role in the synthesis of potential anti-cancer agents, contributing to the advancement of cancer treatment options.
Used in the Synthesis of Antiviral Drugs:
Similarly, 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96% is utilized in the synthesis of antiviral drugs, highlighting its importance in the development of treatments for viral infections.

Upstream product

• 110-91-8 morpholine 
• 5767-35-1 6-chloro-4-hydrazinopyrimidine 
• 1193-21-1 4,6-dichloropyrimidine 
• 22177-92-0 4-(6'-chloropyrimidin-4'-yl)morpholine 

Downstream Products

• 1375799-59-9 sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate 

Relevant academic research and scientific papers

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS

The present invention relates to a process for preparing 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol (I—enol form) or 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one (I—keto form) and sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (II) from 1,2,3-triazole (III), methyl bromoacetate (IV-Me-Br) or ethyl bromoacetate (IV-Et-Br), 4,6-dichloropyrimidine (VIII), morpholine (IX) and hydrazine (XII).

SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES

The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.

PEPTIDE DEFORMYLASE INHIBITORS

Novel PDF inhibitors and novel methods for their use are provided.